ストックスクリーナーアプリを入手
0.387
7.50%
0.027
アフターアワーズ：
.38
-0.007
-1.81%
前日終値:
$0.36
開ける：
$0.365
24時間の取引高:
143.16K
Relative Volume:
0.75
時価総額：
$5.95M
収益：
-
当期純損益:
$-19.09M
株価収益率:
-0.1783
EPS:
-2.17
ネットキャッシュフロー:
$-16.92M
1週間 パフォーマンス:
-3.27%
1か月 パフォーマンス:
+4.88%
6か月 パフォーマンス:
-34.13%
1年 パフォーマンス:
-64.00%
1日の値動き範囲:
$0.35
$0.39
1週間の範囲:
$0.341
$0.4311
52週間の値動き範囲:
$0.3154
$1.74
Organovo Holdings Inc Stock (ONVO) Company Profile
名前
Organovo Holdings Inc
セクター
電話
858-224-1000
住所
11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA
ONVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONVO
Organovo Holdings Inc
|
0.387 | 5.95M | 0 | -19.09M | -16.92M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Organovo Holdings Inc Stock (ONVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-12-13 | 開始されました | H.C. Wainwright | Buy |
| 2017-11-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 開始されました | Raymond James | Outperform |
| 2015-08-11 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 開始されました | Jefferies | Buy |
| 2015-06-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Organovo Holdings Inc (ONVO) 最新ニュース
Organovo faces potential Nasdaq delisting - MSN
3D Bioprinting in Medical Market Worth $4.9 billion by 2032 | - openPR
Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Organovo names new CFO amid clinical advancements By Investing.com - Investing.com Nigeria
Organovo Appoints Norman Staskey as Chief Financial Officer - citybiz
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - The Manila Times
Organovo names new CFO amid clinical advancements - Investing.com
Organovo Appoints M&A Veteran CFO as FXR314 Drug Shows Promising Phase 2 Results - StockTitan
Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com - Defense World
Organovo appoints new president and CFO amid strategic plans By Investing.com - Investing.com Nigeria
Organovo appoints new president and CFO amid strategic plans - Investing.com India
Organovo Holdings Appoints Norman Staskey as New CFO - TipRanks
Organovo (NASDAQ:ONVO) Now Covered by StockNews.com - Defense World
Analyzing Sorrento Therapeutics (OTCMKTS:SRNEQ) and Organovo (NASDAQ:ONVO) - Defense World
Healthcare 4D Printing Market Top Companies Study3D Systems - openPR
3D Print Organ Market 2024 to Witness Huge Growth by 2032 Prominent Players are Organovo Holdings, EnvisionTEC - openPR
3D Bioprinting for Tissue and Organ Regeneration Market Top - openPR
3D Bioprinting Equipment Sales Market Overview, Future Trends - openPR
3D-Printed Organs Market is experiencing new opportunities & competitive edge highlighted by Top Market Key Players (Organovo Holdings Inc., Modern Meadow, Poietis, REGEMAT 3D S.L., Cellbricks, Nano3D Biosciences, Inc.) | Forecast to 2030 - Industry Today
Empowering Growth: Bioprinting Services Market 2024 - openPR
3D Bioprinting Market is Forecast to Achieve USD 2.0 Billion - openPR
ONVO (Organovo Holdings) Enterprise Value : $5.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Organovo expands equity incentive plan following stockholder approval By Investing.com - Investing.com Nigeria
Organovo expands equity incentive plan following stockholder approval - Investing.com
Organovo Holdings Gains Approval for Key Strategic Moves - TipRanks
Industrial 3D Printing Market Size Analysis and Top Companies - Precedence Research
ONVOOrganovo Holdings Inc. Latest Stock News & Market Updates - StockTitan
Organovo reports positive Phase 2 results for liver drug FXR314 By Investing.com - Investing.com Australia
Organovo reports positive Phase 2 results for liver drug FXR314 - Investing.com India
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - The Manila Times
Organovo's FXR314 Shows Significant Liver Fat Reduction in Phase 2 MASH Trial | ONVO Stock News - StockTitan
Human Liver Models Market 2024-2031| Emerging Technologies, - openPR
Organovo stock plunges to 52-week low of $0.35 amid market challenges - Investing.com India
3D Bioprinting Market Projected to Reach $$$ Billion by 2031 with - openPR
Armistice Capital, LLC Increases Stake in Organovo Holdings Inc - GuruFocus.com
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight - GlobeNewswire Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - The Manila Times
Organovo's FXR314 Drug Trial Data Selected for Major Liver Conference Presentation | ONVO Stock News - StockTitan
3D Printer Market to Grow by USD 30 Billion (2024-2028), Driven by Rising Consumer Demand for Customized Products, AI-Powered Report Highlights Market TransformationTechnavio - The Malaysian Reserve
Is Health Care's Hottest Stock a Mirage? - AOL
Organovo: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
Organovo Holdings Inc (ONVO) Quarterly 10-Q Report - Quartzy
Organovo stock plunges to 52-week low of $0.39 amid market challenges - Investing.com Australia
Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Organovo stock plunges to 52-week low of $0.42 amid market challenges - Investing.com Canada
Organovo Holdings Inc (ONVO) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):